Ownership and insider activity for Septerna Inc (SEPN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Price
| Price | $38.44 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-08 | Patni Rajiv | A-Award | 275,000 | $10.3M |
| 2026-08-24 | Patni Rajiv | |||
| 2026-09-01 | Long Daniel D. | M-Exempt | 3,333 | $9K |
| 2026-09-01 | Long Daniel D. | S-Sale | 3,333 | $126K |
| 2026-09-01 | Long Daniel D. | M-Exempt | 3,333 | $9K |
| 2026-08-12 | Third Rock Ventures V, L.P. | S-Sale | 147,059 | $7.4M |
| 2026-08-12 | Third Rock Ventures V, L.P. | S-Sale | 141 | $7K |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 746,500 | $31.7M |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. | S-Sale | 746,500 | $31.7M |
| 2026-08-11 | Bhatt Elizabeth | M-Exempt | 6,319 | $17K |
Balance Sheet (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $30.6M | $88.5M | $238.2M | $120.7M |
| Short-term Investments | 0 | 0 | $112.7M | $270.4M |
| Receivables | 0 | $22.8M | $1.1M | $13.7M |
| Inventory | 0 | 0 | 0 | 0 |
| Total Current Assets | $31.9M | $112.7M | $356.8M | $411.0M |
| Property, Plant & Equipment | $3.1M | $17.2M | $28.7M | $25.9M |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Total Assets | $36.1M | $130.9M | $456.6M | $596.2M |
| Accounts Payable | $3.1M | $2.6M | $3.2M | $10.3M |
| Short-term Debt | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $5.5M | $6.9M | $12.8M | $86.9M |
| Long-term Debt | 0 | 0 | 0 | $21.4M |
| Total Liabilities | $80.3M | $169.2M | $36.5M | $214.3M |
| Retained Earnings | -$50.8M | -$46.6M | -$118.4M | -$167.3M |
| Total Equity | -$44.2M | -$38.4M | $420.0M | $381.9M |
| Total Debt | $710000 | $12.6M | $25.5M | $23.6M |
| Net Debt | -$29.9M | -$75.9M | -$325.4M | -$367.5M |
| Working Capital | $26.3M | $105.8M | $344.0M | $324.0M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 4.99 |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -8.89% |
| Return on Assets | -4.28% |
| Gross Margin | 99.57% |
| Operating Margin | -44.04% |
| Net Margin | -24.51% |
Related companies: ABUS · BCAX · EYPT · FTRE · KURA · MRVI · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks